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REVIEW 
The Mediators of Bile Action on the Exocrine Pancreas* 
In a recent review (1) evidence was presented that intraduo- 
denally applied bile and certain bile salts dose-dependently 
increase basal and hormonally stimulated hydrokinetic and 
ecbolic pancreatic function in man and animals. In con- 
trast, bile and bile salts have no effect or even reduce pan- 
creatic secretion stimulated by intraduodenal nutrient 
compounds. Moreover, species differences, particularly 
with regard to the rat, have been discussed. 
A direct action of bile salts on the pancreas via the cir- 
culation is very unlikely, since the effects of bile salts occur 
immediately after intraduodenal application. Bile salts, how- 
ever, are physiologically absorbed in the terminal ileum. 
Therefore, hormones and/or neural mechanisms must be 
assumed to be mediators. 
HORMONAL MEDIATORS 
In this section, gastroenteropancreatic peptides released by 
bile or bile salts will be discussed in accordance with their 
action on the exocrine pancreatic secretion. 
Gastroenteropancreatic peptides with stirnulatory effects 
Secretin. Secretin is the most important hormonal 
mediator of pancreatic volume and bicarbonate secretion 
(2,3). Its effect can be enhanced by other hormones, such 
as cholecystokinin (CCK), and by neural mechanisms (4). 
As early as in 1926, Mellanby ( 5 )  proposed the existence 
of a mediator role for secretin in bile-induced pancreatic 
secretion in anaesthetized cats. Some 50 years later Osnes 
et al. (6,7) were the first to show that intraduodenal appli- 
cation of 6 g of cattle bile induces a significant increase not 
only of pancreatic volume and bicarbonate secretion but also 
of plasma secretin levels in man. A load of 4g  of bile 
followed by a constant infusion of 0.15 g bile/min over a 40- 
min period continuously released secretin and stimulated 
pancreatic secretion as well (8). In addition, plasma secretin 
concentrations rose significantly after intraduodenal appli- 
cation of 2, 4, and 6 g  bile at 65-min intervals, and the 
kinetics of plasma secretin was correlated to that of volume 
and bicarbonate secretion (9). Moreover, integrated plasma 
secretin showed a dose-dependent increase after bile, indi- 
cating a specific effect of bile on secretin release (9). Burhol 
et al. (lo), however, found only a non-significant increase 
of plasma secretin on intraduodenal infusion of 6 g  bile 
in man. On the other hand, an intravenous injection of 
cholecystokinin (CCK), a potent stimulus of gallbladder 
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contraction, did not influence plasma secretin concentrations 
in man (11). The bile secretion, however, was not measured 
in these experiments. In contrast, in the anaesthetized cat, 
instillation of gallbladder bile in the duodenum significantly 
increased plasma secretin concentrations (12). 
Bile salts are the effective constituents of bile with regard 
to stimulation of basal pancreatic secretion (1). A solution 
of pure synthetic bile salts (20ml of a 50-mM solution), 
comparable to human gallbladder bile, increased plasma 
secretin levels significantly in man (13). Furthermore, intra- 
duodenally infused solutions of single bile salts (up to 
90 mM), like Na-glycocholate, Na-cholate, Na-taurocholate, 
and chenodeoxycholate significantly and dose-dependently 
enhanced plasma secretin concentrations (11). The relative 
secretin-releasing potencies of these bile salts in the order 
mentioned above are 1:1.3:1.9:3.2. Pancreatic hydrokinetic 
function, however, was not measured simultaneously in 
these studies (11,13). In a recent study in man (9), not only 
a dose-dependent increase of integrated plasma secretin 
but also a corresponding dose-dependent augmentation of 
volume and bicarbonate secretion after 200,400, and 600 mg 
Na-taurodeoxycholate could be observed. 
The kind of conjugation (taurine or glycine) does not 
influence the hydrokinetic activity and the secretin-releasing 
potency of deoxycholate (14). In contrast, taurocholate 
showed a 1.9-fold greater secretin release than glycocholate. 
The hydrokinetic effect was not registered (11). 
In anaesthetized cats duodenal perfusion (45 ml/h) with 
Na-taurocholate (120 mM), the predominant bile salt in this 
species, increased plasma secretin concentrations and pan- 
creatic flow as well (15). The threshold concentration of Na- 
taurocholate for secretin release was between 10 and 15 mM 
(12). In rats, the hydrokinetic effect of chenodeoxycholate 
was markedly reduced by an intravenous injection of a 
specific secretin antibody (16). 
From these results it may be concluded that secretin acts 
as a mediator of the hydrokinetic effect of bile and bile salts 
on basal pancreatic secretion. 
In contrast to basal (interdigestive) conditions, the 
secretin-releasing effect of Na-taurocholate was significantly 
diminished when the bile salt was dissolved in a liquid meal 
instead of a saline solution in man (11). Reinfusion of 
postprandial aspirate containing 15.8 rnM endogenous bile 
salts did not influence plasma secretin concentrations. 
Enhancing total bile salt concentration up to 30mM by 
addition of chenodeoxycholate, however, resulted in an 
immediate increase of plasma secretin levels (1 1). Whether 
the content of bile salt monomers is reduced during the meal 
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by micelle formation and increased again after the addition 
of chenodeoxycholate to a load releasing secretin is specu- 
lative. After intragastric application of a liquid meal, 
however, no correlation was found between the duodenal 
load of bile acids and plasma secretin concentrations (17). 
These data are in accordance with the hypothesis that bile 
and bile salts do not stimulate nutrient-induced pancreatic 
secretion (1). 
Vasoactiue intestinal peptide (VIP).  VIP, a partial agonist 
of secretin, acts as a hormonal mediator of hydrokinetic 
pancreatic function when infused in pharmacologic doses 
(18, 19). Under physiologic conditions, however, VIP may 
act as a peptidergic neurotransmitter. Since the existence of 
VIP-containing endocrine cells of the gut is questioned as 
well (20), a hormonal action of VIP on the exocrine pancreas 
is unlikely. An increase in peripheral VIP levels represents 
rather a neuronal ‘overflow’ phenomenon (21). Therefore, 
changes in plasma VIP levels after bile and bile salts will be 
discussed below (see section on peptidergic mechanisms). 
Cholecystokinin. CCK is the essential hormonal stimulus 
of pancreatic enzyme secretion (4). In man, only a few data 
are available about bile- or bile salt-induced CCK release. 
A physiologic dose of Na-taurodeoxycholate (0.8 mmol) 
applied intraduodenally caused a significant increase of 
plasma CCK concentrations (22). In earlier studies by Burhol 
et al. (23,24), however, bile, intraduodenally infused in a 
submaximal dose with regard to the stimulatory effect on 
the exocrine pancreas (9), did not affect plasma CCK levels. 
This discrepancy may be due to a different sensitivity and 
specificity of the CCK radioimmunoassays used. On the 
other hand, in patients with a common bile duct obstruction 
due to a malignant tumour, basal CCK concentrations have 
been reported to be either increased (25) or normal (26). 
In conscious starved dogs, perfusion of the duodenum 
with a 3.6- and 12-mM solution of taurocholate (100 ml/h) 
left plasma CCK levels unchanged, although protein output 
of the pancreas was increased (27). Intraduodenal infusion 
of a very high amount of bile even reduced basal plasma 
CCK levels (28). Furthermore, diversion of bile from the 
duodenum and reinfusion to the jejunum (29) or external 
drainage (28) influenced neither basal plasma CCK nor 
pancreatic secretion. 
In conscious starved rats without diversion of bile and 
pancreatic juice, intraduodenal infusion of chenodeoxy- 
cholate (60 mmol/l; 1 ml/h) significantly enhanced pan- 
creatic protein output but not plasma CCK. Administration 
of the specific CCK antagonist CR-1409, however, sig- 
nificantly reduced the ecbolic effect, suggesting that CCK 
plays at least some role in the mediation of the bile salt effect 
in this species (16). 
In contrast to basal conditions, nutrient-induced pan- 
creatic enzyme secretion is reduced by intraduodenal bile or 
bile salts in man, suggesting an impaired CCK release (1,30). 
In accordance with this hypothesis, Gomez et al. (31) noted 
a significant decrease of plasma CCK-33/39 after oral in- 
gestion of an amino acid solution when adding 6mmol of 
taurocholate. Furthermore, 5 and 10 mmol of chenode- 
oxycholate decreased CCK release produced by an orally 
ingested or duodenally perfused liquid test meal (26,32). 
In dogs, CCK-33/39 release stimulated by intraduodenal 
instillation of amino acids and triglycerides was inhibited by 
addition of pooled bile and enhanced by diversion of bile 
from the duodenum (28,31). The latter effect could be 
completely reversed by substituting exogenous bile salts. 
Furthermore, taurocholate added to an intraduodenally per- 
fused fat solution reduced both integrated CCK release and 
pancreatic protein output (27). In contrast, diversion of bile 
from the duodenum by cholecystojejunostomy and bile duct 
ligation decreased meal-stimulated CCK release and trypsin 
secretion rate (29). There is no conclusive explanation for 
these discrepancies. 
In rats, a luminal feedback regulation of pancreatic se- 
cretion is assumed not only due to protease activity, but 
also with regard to bile (33,34). Diversion of bile, pancreatic 
juice, or both from the intestine enhanced plasma CCK 
levels and pancreatic protein output as compared with the 
basal value (35). Conversely, the effects could be impaired 
by intraduodenal infusion of several bile salts (16,36). 
Chronic experiments with bile duct ligation also increased 
basal plasma CCK concentrations (37). On the other hand, 
intraduodenal Na-taurocholate did not inhibit CCK release 
and pancreatic secretion in rats with chronic diversion of 
bile and pancreatic juice (38). This discrepancy may be due 
to the difference in experimental design (bile duct ligation 
versus external drainage of bile and pancreatic juice). 
In mice without exclusion of bile or pancreatic juice, 
meal-stimulated CCK release was also reduced by chronic 
intraduodenal application of Na-taurocholate (39). 
Cholestyramine is a bile salt-binding resin (40) and there- 
fore a valuable tool to elucidate further the effect of intra- 
duodenal bile salts on CCK release and pancreatic secretion. 
Chronic oral treatment with 12 g cholestyramine three times 
daily in man significantly increased basal plasma CCK con- 
centrations after the first day, but this effect was attenuated 
and finally abolished after 4 weeks. Basal enzyme secretion, 
however, remained unchanged (41). In conscious dogs con- 
tinuous intraduodenal infusion of 8 g/h of cholestyramine 
influenced neither plasma CCK-33/39 levels nor protein 
output (31). In guinea pigs and rats, long-term intraduodenal 
application of cholestyramine did not affect basal plasma 
CCK concentrations (42,43). In contrast, CCK release and 
pancreatic enzyme output stimulated by nutrient compounds 
were enhanced by oral or intraduodenal administration ot 
cholestyramine in man (31,32,41,44), dogs (31), guinea 
pigs (42), rats (43), and mice (39). The effect on CCK 
release could be abolished by adding taurocholate (31) or 
chenodeoxycholate (45) to the stimulants. 
An interpretation of the conflicting results about intra- 
duodenal bile or bile salts on CCK release seems to be 
difficult. Although bile or bile salts stimulate basal enzyme 
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secretion, a release of CCK could be demonstrated only by 
a recent study, whereas in earlier investigations no changes 
of plasma CCK were observed. CCK radioimmunoassays 
used in the latter studies, however, showed a low sensitivity 
and specificity. As another explanation for the lack of CCK 
release, the hypothesis stated by Singer may be cited (4). 
Accordingly, high loads of intraduodenal stimulants of the 
exocrine pancreas may predominantly be mediated by 
hormones; low loads, however, are mediated by neural 
mechanisms. 
In contrast to basal conditions, intraduodenal bile or bile 
salts seem to exert an inhibitory action on CCK release and 
on pancreatic enzyme secretion stimulated by intraluminal 
nutrient compounds. These observations are supported by 
the results obtained with cholestyramine. Removal of bile 
salts from the intestine by this resin enhances CCK release 
and pancreatic enzyme secretion stimulated by nutrient com- 
pounds. When evaluating the results, species differences 
have to be considered especially with regard to the rat. In 
this species, bile salts seem to exert an inhibitory effect on 
basal pancreatic enzyme secretion and on  plasma CCK levels 
as well. 
Neurotensin. Besides its neurotransmitter function, 
neurotensin is also a gastrointestinal hormone predominant- 
ly located in the ileum. The peptide increases basal hydro- 
kinetic and ecbolic pancreatic secretion and augments the 
action of endogenously released secretin and CCK stimu- 
lated by HCI and amino acids, respectively (46,47). 
In starved dogs, neither intraduodenal application of bile 
nor bile diversion from the duodenum significantly influ- 
enced plasma neurotensin levels (28). Triglyceride-induced 
neurotensin release, however, was significantly enhanced by 
diversion of bile from the intestine. The effect is probably 
due to a delayed absorption with exposure of a longer part 
of the gut to fat rather than to  an inhibitory action of bile 
on neurotensin release, since addition of bile did not diminish 
triglyceride-induced neurotensin release (28). In contrast, 
neurotensin release was further increased by addition of 2 g 
chenodeoxycholate to a cholestyramine-supplemented meal 
in man (48). 
The contradictory results are probably due to species 
differences. Further studies, however, are  needed to specify 
the releasing mechanisms of neurotensin and the role of bile. 
Gastroenteropancreatic peptides without physiologic effect 
(on the exocrine pancreas) 
Gastric inhibitory polypeptide (GIP)  . In its primary struc- 
ture, GIP is related to  secretin and VIP. In physiologic 
doses, however, this peptide exerts no effect on the exocrine 
pancreas (49). After intraduodenal application of 6 g of 
bile in man plasma concentrations of GIP were moderately 
increased (10,50), whereas duodenal perfusion with Na- 
taurocholate showed no influence (51). In dogs, adminis- 
tration of bile into the upper jejunum left plasma GIP levels 
unchanged (52,53). 
In spite of the few studies, bile does not seem to be an 
essential stimulus of GIP release. 
Gastrin. In  physiologic doses, gastrin does not influence 
exocrine pancreatic secretion (54). Intraduodenal appli- 
cation of bile or Na-taurodeoxycholate caused only a 
marginal, dose-independent increase of plasma gastrin 
concentrations in man (9, 14,55,56). Furthermore, intra- 
duodenal perfusion with Na-taurocholate did not enhance 
plasma gastrin levels and pancreatic secretion (51). In dogs, 
bile infusion into the upper jejunum left plasma gastrin 
concentrations unchanged (52). Diversion of bile from the 
duodenum by cholecystojejunostomy and bile duct ligation 
caused a late rise in serum gastrin levels and a decrease in 
trypsin secretion (29,57). In contrast, by-passing bile into 
the ileum decreases gastrin release (58). 
From these data it can be concluded that gastrin does not 
play any role in the mediation of the bile effect on  pancreatic 
secretion. 
Gastroenteropancreatic peptides with an inhibitory effect 
Somatostatin. In a dosage reproducing postprandial 
plasma levels, somatostatin is able to inhibit exocrine pan- 
creatic secretion, indicating its physiologic counterregulat- 
ory action (59). In man, intraduodenal application of 2 
to 6 g bile and 200 to 600 mg Na-taurodeoxycholate dose- 
dependently increased plasma somatostatin concentrations 
simultaneously with a stimulation of exocrine pancreatic 
secretion (60). Somatostatin levels observed after the 
respective highest dose were in the range of postprandial 
concentrations. In contrast, Burhol e t  al. (61) were not able 
to show a significant rise in peripheral plasma somatostatin 
after intraduodenal application of 3 g bile. 
In dogs, intraduodenal infusion of 3 g  bile induced a 
marked release of somatostatin in portal plasma comparable 
to that found after intragastric fat infusions (62). 
Although there are only a few studies, a physiologically 
relevant release of somatostatin by bile or bile salts may be 
assumed. 
Pancreatic polypeptide (PP).  PP is released by a meal or 
nutrient compounds. The release is mediated by cholinergic 
mechanisms and CCK. In physiologic doses P P  exerts an 
inhibitory action on exocrine pancreatic secretion (63). In 
man, intraduodenal application of 2 to 6 g  bile and 200 to 
600 mg Na-taurodeoxycholate dose-dependently increased 
not only exocrine pancreatic secretion but also plasma PP 
concentrations (9). Postprandial PP levels, however, were 
not reached. The PP-releasing effect was independent of the 
mode of conjugation (14). On the other hand, intraduodenal 
Na-taurocholate influenced neither plasma PP levels nor 
pancreatic enzyme secretion (51). Addition of 2 g cheno- 
deoxycholate to a Lundh meal did not modify plasma PP 
levels, although trypsin output was significantly enhanced 
(44). Six grams of cholestyramine left meal-stimulated PP 
release unchanged (44), whereas 12 g of this resin caused a 
twofold increase (41). The latter induced higher plasma 
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CCK levels, probably being responsible for the PP release 
observed. 
From these studies it may be concluded that PP is only of 
minor importance as a counterregulatory hormone of the 
bile effect on pancreatic secretion. 
NEURAL MEDIATION 
Cholinergic mechanisms 
Pancreatic hydrokinetic and ecbolic function is enhanced 
by cholinergic stimulation (4,64,65). Furthermore, cholin- 
ergic mechanisms may enhance the action of endogenously 
released secretin and CCK. Only two studies, however, have 
been carried out to reveal the role of cholinergic mechanisms 
in the bile- or bile salt-induced exocrine pancreatic secretion. 
In man, atropine clearly reduced the ecbolic effect of 
intraduodenal bile (66). Pancreatic enzyme secretion stimu- 
lated by 2 to 6 g  intraduodenal bile could be almost com- 
pletely abolished by propantheline, an anticholinergic drug 
with an additional ganglionic-blocking effect (66,67). On 
the other hand, volume and bicarbonate secretion were 
not changed. There is, however, no information about the 
suppression of the cholinergic tone influencing the action of 
CCK, as the effect of the anticholinergic drugs on CCK- 
induced pancreatic secretion was not investigated simul- 
taneously. 
PP is considered a hormone under vagal control (68) and 
may thus serve as an indirect marker of the involvement of 
cholinergic mechanisms. Indeed, plasma PP concentrations 
dose-dependently increased after intraduodenal bile and 
taurodeoxycholate, and the kinetics was correlated to that 
of trypsin secretion rate (9). However, PP is also released by 
CCK (69). Nevertheless, the amount of CCK concomitantly 
released by Na-taurodeoxycholate may not be adequate to 
explain the PP release observed. 
Considering these studies, the ecbolic effect of bile may 
at least partially be mediated by cholinergic mechanisms. 
On the other hand, cholinergic mechanisms do not seem to 
play an essential role in the mediation of the hydrokinetic 
action. 
Adrenergic mechanisms 
Sympathetic nerves probably are not involved in the post- 
prandial pancreatic secretion (70). With regard to the bile- 
or bile salt-induced pancreatic secretion no data are available 
about the influence of the sympathetic nervous system. 
Peptidergic mechanisms 
Besides the classical neurotransmitters, a third group con- 
sisting of several regulatory peptides has been established. 
In the pancreas, VIP-containing nerve endings have been 
detected. They are localized in close association with the 
pancreatic ducts (71) responsible for water and bicarbonate 
secretion. Moreover, in the isolated pig pancreas, electric 
stimulation of the vagus nerve caused a VIP release and an 
atropine-resistant hydrokinetic response as well (71,72). 
Therefore, VIP may play a physiologic role in the mediation 
of water and bicarbonate secretion (73). 
Intraduodenal application of a single dose of 6 g  bile 
significantly enhanced plasma VIP levels and hydrokinetic 
pancreatic function in man (10). Moreover, 2 ,4 ,  and 6 g bile 
dose-dependently increased plasma VIP concentrations and 
integrated VIP concomitantly with volume and bicarbonate 
secretion (60). This rise in peripheral plasma VIP con- 
centrations may be explained by an ‘overflow’ phenomenon 
of VIP from the synaptic cleft into the venous effluent. 
Therefore, VIPergic nerves may be involved in the mediation 
of the hydrokinetic effect of bile, although VIP is only a 
weak stimulus as compared with secretin (74). As bile was 
applied into the duodenum, the possibility cannot be com- 
pletely excluded, however, that VIP measured in peripheral 
plasma partly originated from VIPergic neurons of the sub- 
mucous or the myenteric plexus of the gut. 
Gastrin-releasing peptide (GRP), a further regulatory 
peptide localized in nerve fibre endings of the pancreas, is 
able to stimulate pancreatic secretion (75). Studies on the 
effect of bile or bile salts on GRP release, however, have 
not yet been performed. 
SUMMARY 
Under basal conditions, bile and bile salts applied intra- 
duodenally influence plasma levels of several gastro- 
enteropancreatic peptides. Besides those with stimulatory 
effects on exocrine pancreatic secretion, others with inhibi- 
tory or no effects are released as well. Furthermore, chol- 
inergic and peptidergic neural mechanisms may also be 
activated. Secretin seems to be the most important mediator 
of bile- or bile salt-induced water and bicarbonate secretion. 
In addition, VIP released from peptidergic nerve endings in 
the pancreas may also be involved in the mediation of the 
hydrokinetic effect. With regard to water and bicarbonate 
secretion, cholinergic mechanisms probably are of minor 
importance. 
Cholinergic mechanisms, however, seem to be the most 
important mediator of bile- or bile salt-induced pancreatic 
enzyme secretion. CCK may act as an additional mediator 
of the ecbolic effect. This statement, however, is based on 
few results only and has to be confirmed by further studies. 
Gastroenteropancreatic peptides with an inhibitory action 
on the exocrine pancreas were also released by intraduo- 
denal bile or bile salts. Somatostatin is released in physio- 
logically relevant amounts to bring about a counter-regu- 
lation. Plasma PP levels are also enhanced by bile and 
bile salts. The amounts of PP released, however, are below 
those observed postprandially. 
In contrast to their stimulatory action on basal pancreatic 
secretion, bile and bile salts have no or even an inhibitory 
effect on pancreatic secretion stimulated by intraluminal 
nutrients. Accordingly, the release of gastroenteropan- 
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creatic peptides is not influenced (for example, secretin) or 
even reduced (for example, CCK) when bile or bile salts are 
added to intraluminal nutrients. Conversely, removal of bile 
salts from the intestine by cholestyramine further enhances 
plasma CCK concentrations during nutrient stimulation. 
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